Best Life Sciences Companies in Perth, Australia
The 36 best Life Sciences companies in Perth, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Creso Pharma.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Perth
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Creso Pharma Developer of cannabinoid therapeutics for multiple health purposes | $28M | 71 mo ago | Acquired | Marc Lustig CEO | 2015 | — | — | — |
| 2 | SUDA Pharmaceuticals Developer of oro-mucosal drug delivery technology for treating multiple diseases | $24M | 62 mo ago | Public | Stephen Carter Chairman & CEO | 1999 | — | 7 patents Therapies targeting platelet‑mediated metastasis in thrombocytotic cancer patients | — |
| 3 | Arovella Therapeutics Developer of cell therapies to treat cancer and neurological diseases | $23M | 20 mo ago | Public | — | 1999 | — | 2 patents Repurposed antiplatelet drug anagrelide for oncology, targeting metastatic thrombocytosis. | — |
| 4 | Proteomics International Medical technology company at the forefront of predictive diagnostics and bio-analytical services | $16M | 31 mo ago | Public | Richard Lipscombe Co-Founder & Managing Director | 2001 | WordPressMySQLPHP+11 | — | — |
| 5 | OncoRes Medical Developer of intraoperative imaging technology for surgical procedures 45Patents top 29%Funding top 32%Moat top 32%Innovation top 34% All 8 signals ▾Patentstop 29% Fundingtop 32% Moattop 32% Innovationtop 34% Newstop 39% Techtop 45% Globalbottom 35% Marketbottom 34% Patents: 48 patents matched (strict assignee match) · 23 filings since 2022 vs 25 in 2017-21 Funding: Raised $13.9M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $14M | 7 mo ago | Series B | — | 2014 | WixSentryEnvoy+15 | 48 patents Medical elastography imaging devices for assessing tissue mechanical properties | — |
| 6 | Orthocell Developer of regenerative medicine for orthopedic diseases | $11M | 22 mo ago | Public | Paul Anderson Founder & CEO | 2006 | WordPressApple iCloud MailMicrosoft 365+28 | 94 patents Collagen-based regenerative implants and devices for tissue repair and orthopedic healing | — |
| 7 | PharmAust Developer of medicines for the treatment of neurodegenerative diseases | $5M | 53 mo ago | Public | — | 2000 | — | — | — |
| 8 | Neurotech International Developer of therapeutics for multiple paediatric neurological disorders | $3M | 107 mo ago | Public | — | 2016 | WordPress Block EditorWordPressMySQL+21 | — | — |
| 9 | Avicena Systems Developer of biosecurity platform and hardware for pathogen testing | $3M | 31 mo ago | Funding Raised | Tony Fitzgerald Co-Founder & CEO | 2020 | — | 22 patents High-throughput biological screening and analysis instruments for pathogen and genetic detection | — |
| 10 | Oz Sonotek Ultrasound-based cataract surgery devices | $1M | 185 mo ago | Deadpooled | Nigel Morlet Founder | 2011 | — | — | — |
| 11 | Nemgenix Developer of plant-resistant traits | $593K | 164 mo ago | Funding Raised | Sean Hird Co-Founder & CEO | 2007 | — | — | — |
| 12 | Cortical Dynamics Developing a brain function monitor which acquires EEG data of anesthetized patients | $250K | 78 mo ago | Seed | — | 2004 | — | 42 patents Non‑invasive brain activity measurement and monitoring devices for clinical neuro‑diagnostics | — |
Top 12 Life Sciences companies in Perth
#1
Series B · Perth, Western Australia · founded 2014 · 31 employees$13.9Mraised▾
Developer of intraoperative imaging technology for surgical procedures. The company utilizes a combination of optical coherence tomography imaging and elastography to provide a rapid evaluation of tissue microarchitecture at a scale and resolution comparable to histology. on the development of an imaging probe that will enable breast cancer surgeons to identify residual cancer following the excision of a tumor, providing a solution to address the high re-excision rates for breast cancer patients.
- Feb 2026Series B$19.2M
- Oct 2022Grant (prize money)$942.2K
- May 2022Grant (prize money)$3M
- May 2022Series A$9.5M
#2
Public · Perth, Western Australia · founded 1999 · 44 employees$23Mraised▾
Developer of cell therapies to treat cancer and neurological diseases. The company is focusing on the development of a natural killer T (iNKT) cell therapy platform for the treatment of human diseases. ZolpiMist is a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. The company is developing other products to treat migraine, headaches, motion sickness, blood cancers, malignant tumors, and drug-resistant epilepsy.
- Jan 2025Post IPO$20M
- Jan 2022Post IPO$3M
#3
Public · Perth, Western Australia · founded 2006$11.2Mraised▾
Developer of regenerative medicine for orthopedic diseases. It offers Striate+ a resorbable collagen membrane for dental applications, Remplir a collagen scaffold for peripheral nerve repair, and OrthoACI autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle.
- Oct 2024Post IPO$11.2M
#4
Public · Perth, Western Australia · founded 2001$15.5Mraised▾
Medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company develop and commercializes diagnostic tests known as PromarkerD, for the detection of diabetic kidney disease. Company specialises in the area of proteomics, the industrial scale study of the structure and function of proteins. It also, offers analytical services for research purposes. The technology can be used to identify fingerprints from any biological source, from wheat seeds to human serum.
- Jan 2024Post IPO$4.3M
- Aug 2022Post IPO$5.7M
- May 2022Grant (prize money)$413.5K
- Nov 2021Grant (prize money)$74.6K
#5
Public · Perth, Western Australia · founded 1999$23.9Mraised▾
Developer of oro-mucosal drug delivery technology for treating multiple diseases. The company utilizes its proprietary OroMist, an oro-mucosal drug delivery technology to develop drugs that improve the health and lifestyle of patients. It offers ZolpiMist, an oral spray of zolpidem for insomnia; ArTiMist, a sub-lingual spray in the development stage for the treatment of malaria in children. The product pipeline also includes oral sprays of sumatriptan for migraine (SUD-001), ondansetron for chemotherapy-induced nausea and vomiting (SUD-002), sildenafil for erectile dysfunction (SUD-003) and PAH (SUD-004), and midazolam for pre-procedural anxiety (SUD-005).
- Jun 2021Post IPO$3.6M
- Dec 2020Post IPO$2.7M
- Aug 2020Post IPO$4.1M
- Nov 2013Post IPO$5.6M
#6
Acquired · Perth, Western Australia · founded 2015 · 23 employees$27.5Mraised▾
Developer of cannabinoid therapeutics for multiple health purposes. The company has developed therapeutics for human and veterinary applications using nanotechnology. The company's lead products are cannabidiol hemp oil-based complementary feed for companion animals and a nutraceutical for human health.
- Oct 2020Post IPO—
- Jun 2020Post IPO$1.4M
- Jan 2019Post IPO$3M
- Nov 2017Post IPO$17.5M
#7
Funding Raised · Perth, Western Australia · founded 2020 · 20 employees$3Mraised▾
Developer of biosecurity platform and hardware for pathogen testing. The company has developed a technology for testing pathogens. They created the Avicena Sentinel, a molecular diagnostics platform with an hourly screening capacity of thousands of samples. Additionally, they are engaged in the development of microLED-based ultra-low energy optical links.
- Feb 2024Grant (prize money)$3M
#8
Public · Perth, Western Australia · founded 2000 · 52 employees$5.2Mraised▾
Developer of medicines for the treatment of neurodegenerative diseases. It offers monepantel a potent inhibitor of the mTOR pathway for cell growth and proliferation of cells that egulates autophagic flux and the recycling of cellular macromolecules for the treatment of motor neurone disease in humans such as Alzheimer’s and Parkinson’s disease.
- Apr 2022Grant (prize money)$201K
- Sep 2020Grant (prize money)$881.1K
- Mar 2015Post IPO$3.1M
- Oct 2013Post IPO$1M
#9
Public · Perth, Western Australia · founded 2016 · 4 employees$3.2Mraised▾
Developer of therapeutics for multiple paediatric neurological disorders. The company's product line include NTI164, is a broad-spectrum oral cannabinoid therapy targeting neuroinflammation in conditions like Autism Spectrum Disorder, Rett Syndrome, and PANDAS/PANS.
- Oct 2017Post IPO$3.2M
#10
Deadpooled · Perth, Western Australia · founded 2011$1.1Mraised▾
Oz Sonotek was developing technology to better manage ultrasound energy during cataract surgery. First product was a needle for phacoemulsification cataract surgery. Company has been closed since 2014.
- Apr 2011Seed$1M
#11
Funding Raised · Perth, Western Australia · founded 2007$593Kraised▾
Developer of plant-resistant traits. It is involved in the development of novel crop traits for plant-parasitic nematodes and aphids resistance. It plans to utilize a technology that exploits the cellular mechanism called RNA interference(RNAi). In RNAi gene expression is inhibited, silenced through the destruction of micro RNA.
- Dec 2012Grant (prize money)$207K
- Jan 2010Grant (prize money)$386K
#12
Seed · Perth, Western Australia · founded 2004 · 8 employees$250Kraised▾
Developing a brain function monitor which acquires EEG data of anesthetized patients. The main product is the Brain Anaesthesia Response (BARM) monitor that is being developed for detecting the effect of anesthetic agents on brain activity. The unit functions as a sensor placed upon the forehead of the patient and gives readings on a dedicated screen. It will aid the anesthetists in keeping patients optimally anesthetized.
- Mar 2020Seed$250K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Australia
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 861 Australia-affiliated papers.
- University College London67
- The University of Queensland63
- The University of Melbourne59
- Agriculture and Food54
- La Trobe University35
- Mutant2→11
- Genome1→7
- Immune system1→5
- Antibody1→4
- Mitochondrion2→4
- Gene5→17
- Immune system2→13
- Antibody1→10
- Messenger RNA1→10
- Mutant1→9
- Agriculture5→19
- Sustainability3→8
- Emerging technologies1→4
- Resistance (ecology)3→6
- Bacteria2→5
Where biotechnology is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.